TY - JOUR
T1 - Casein Hydrolysate with Glycemic Control Properties
T2 - Evidence from Cells, Animal Models, and Humans
AU - Drummond, Elaine
AU - Flynn, Sarah
AU - Whelan, Helena
AU - Nongonierma, Alice B.
AU - Holton, Thérèse A.
AU - Robinson, Aisling
AU - Egan, Thelma
AU - Cagney, Gerard
AU - Shields, Denis C.
AU - Gibney, Eileen R.
AU - Newsholme, Philip
AU - Gaudel, Celine
AU - Jacquier, Jean Christophe
AU - Noronha, Nessa
AU - Fitzgerald, Richard J.
AU - Brennan, Lorraine
N1 - Publisher Copyright:
© 2018 American Chemical Society.
PY - 2018/5/2
Y1 - 2018/5/2
N2 - Evidence exists to support the role of dairy derived proteins whey and casein in glycemic management. The objective of the present study was to use a cell screening method to identify a suitable casein hydrolysate and to examine its ability to impact glycemia related parameters in an animal model and in humans. Following screening for the ability to stimulate insulin secretion in pancreatic beta cells, a casein hydrolysate was selected and further studied in the ob/ob mouse model. An acute postprandial study was performed in 62 overweight and obese adults. Acute and long-term supplementation with the casein hydrolysate in in vivo studies in mice revealed a glucose lowering effect and a lipid reducing effect of the hydrolysate (43% reduction in overall liver fat). The postprandial human study revealed a significant increase in insulin secretion (p = 0.04) concomitant with a reduction in glucose (p = 0.03). The area under the curve for the change in glucose decreased from 181.84 ± 14.6 to 153.87 ± 13.02 (p = 0.009). Overall, the data supports further work on the hydrolysate to develop into a functional food product.
AB - Evidence exists to support the role of dairy derived proteins whey and casein in glycemic management. The objective of the present study was to use a cell screening method to identify a suitable casein hydrolysate and to examine its ability to impact glycemia related parameters in an animal model and in humans. Following screening for the ability to stimulate insulin secretion in pancreatic beta cells, a casein hydrolysate was selected and further studied in the ob/ob mouse model. An acute postprandial study was performed in 62 overweight and obese adults. Acute and long-term supplementation with the casein hydrolysate in in vivo studies in mice revealed a glucose lowering effect and a lipid reducing effect of the hydrolysate (43% reduction in overall liver fat). The postprandial human study revealed a significant increase in insulin secretion (p = 0.04) concomitant with a reduction in glucose (p = 0.03). The area under the curve for the change in glucose decreased from 181.84 ± 14.6 to 153.87 ± 13.02 (p = 0.009). Overall, the data supports further work on the hydrolysate to develop into a functional food product.
KW - casein
KW - hydrolysate
KW - insulin
KW - nutrition
KW - postprandial glycemia
UR - http://www.scopus.com/inward/record.url?scp=85046406020&partnerID=8YFLogxK
U2 - 10.1021/acs.jafc.7b05550
DO - 10.1021/acs.jafc.7b05550
M3 - Article
C2 - 29638124
AN - SCOPUS:85046406020
SN - 0021-8561
VL - 66
SP - 4352
EP - 4363
JO - Journal of Agricultural and Food Chemistry
JF - Journal of Agricultural and Food Chemistry
IS - 17
ER -
